This year’s top diabetes content focused on pediatric metabolic health, misconceptions about weight loss drugs, and more.
The most-viewed diabetes stories of 2024 highlighted key advancements and challenges in diabetes care, from groundbreaking FDA approvals to ongoing debates about treatment approaches. These top articles and interviews covered topics such as pediatric metabolic health, misconceptions about glucagon-like peptide 1 (GLP-1) receptor agonists, affordability barriers, and the implications of treatment disruptions.
Here are the 5 most-viewed diabetes pieces of 2024. You can check out the rest of our diabetes news here.
At an Institute for Value-Based Medicine® event this year, Robert Lustig, MD, MSL, endocrinologist and professor emeritus of pediatrics at the University of California, San Francisco, argued for a shift from focusing on obesity to addressing metabolic dysfunction, which affects 93% of Americans, including children. In this interview, he explained how sugar drives type 2 diabetes and fatty liver disease in children, likening its effects to alcohol on the liver. Lustig also called for shifting health care metrics from body mass index to measures like waist circumference and fasting insulin to address the root causes of metabolic dysfunction.
A survey of over 1500 individuals with diabetes uncovered significant misconceptions, including the belief among 57% of respondents that GLP-1 weight loss drugs alone can manage their health. Arti Masturzo, MD, MBA, chief medical officer of CCS, said these drugs should be part of a comprehensive care strategy involving personalized education, coaching, and medical device support. The survey also revealed gaps in patient engagement, with many seeking more support between doctor visits and better initial education at diagnosis.
The top diabetes content focused on pediatric metabolic health, new diabetes management options, and more. | Image credit: Sherry Young – stock.adobe.com
A KFF Health Tracking Poll revealed that affordability remains a significant challenge for GLP-1 users, with over half of insured adults still paying out-of-pocket costs. The survey highlighted diverse uses for these drugs, with 39% using them for chronic conditions like diabetes or heart disease and 38% for weight loss. Public awareness of GLP-1s has surged, but barriers like high prices and limited Medicare coverage persist, particularly for weight loss purposes.
In this interview from January, Ian Neeland, MD, University Hospitals Harrington Heart & Vascular Institute, discussed the risks for patients with diabetes who face semaglutide shortages; these include losing glycemic control, experiencing symptoms of uncontrolled diabetes, and facing adverse events. Neeland also emphasized the challenges of switching medications, as alternative options may lack the cardiovascular and kidney benefits of GLP-1 receptor agonists. Improper reintroduction of semaglutide at previously stable doses can also cause severe side effects, highlighting the need for patient education and careful management.
In March, the FDA approved the Dexcom Stelo Glucose Biosensor System, the first continuous glucose monitor (CGM) available over the counter. Designed for adults not requiring insulin therapy, the system helps track glucose levels through a smartphone app, with each wearable sensor lasting 15 days. This milestone expands access to CGMs, empowering individuals with or without diabetes to monitor their glucose levels without needing a prescription.
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Top Pharmacy Leaders to Convene at Asembia’s AXS25 Summit in Las Vegas
April 24th 2025Asembia's AXS25 Summit will unite more than 8000 key decision-makers to explore pharmacy innovation, artificial intelligence, policy, and patient care from April 27 to May 1 at Wynn & Encore in Las Vegas, Nevada.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More